Stock listing
Propanc Biopharma, Inc.
Selected listing: PPCB · NASDAQ · USD · US
Propanc Biopharma, Inc. (NASDAQ:PPCB), Health Technology. Latest release Sep 29, 2026: Propanc Biopharma Provides Corporate Update & Year-End June 30…
- Ticker
- NASDAQ:PPCB
- Asset type
- Stock
- Sector
- Health Technology
- Industry
- Biotechnology
- Exchange
- NASDAQ
- Currency
- USD
About Propanc Biopharma, Inc.
Propanc Biopharma, Inc. is a public company traded under the ticker PPCB in the American market. Propanc focuses on developing innovative therapies for cancer treatment.
Latest news from Propanc Biopharma, Inc.
Propanc Biopharma Provides Corporate Update & Year-End June 30, 2025-26, Financial Results
September 28, 2026
Propanc Biopharma Highlights Differentiated PRP Pancreatic Cancer Data Versus Emerging Pan-RAS Program ERAS-0015
September 22, 2026
Propanc Biopharma Positions PRP’s EMT-Reversal Mechanism as a Complementary Backbone to Emerging RAS Inhibitors from Revolution Medicines, Inc. and Erasca, Inc.
September 16, 2026
Propanc Biopharma to Initiate World-First Phase 1b First-in-Human Study of PRP in February 2027
September 9, 2026
Propanc Biopharma Announces Compelling New Preclinical Pancreatic Cancer Data for PRP Showing >90% Tumor Growth Inhibition and >2.5-Fold Survival Benefit
August 27, 2026
Research Propanc Biopharma, Inc.
Propanc Biopharma, Inc. company profile
View the public company page for Propanc Biopharma, Inc. on 6ix.
Propanc Biopharma, Inc. news
Read company news and market updates connected to Propanc Biopharma, Inc..
Propanc Biopharma, Inc. investor events
Find investor webinars, events, and replay context for Propanc Biopharma, Inc..